https://www.thebodypro.com/author/treatment-action-group

Latest by Treatment Action Group

David Baltimore and Vectored Immunoprophylaxis

In November 2011, the laboratory of Nobel laureate David Baltimore published encouraging results from humanized mouse studies of an approach to HIV prevention they have named vectored immunoprophylaxis (assigned the slightly uncomfortable acronym VIP...

Dendritic Cell-Based Therapeutic HIV Vaccine Transiently Modulates Viral Load

A study published in the January 2 issue of Science Translational Medicine reports that a dendritic cell (DC)-based therapeutic HIV vaccine was able to significantly lower viral load after an antiretroviral therapy (ART) interruption, albeit only tra...

Immune Reconstitution Syndrome (IRS/IRIS)

Lymph Node Fibrosis, CD4 T Cells, and Immune Reconstitution

One of the less well-publicized consequences of the persistent immune activation caused by HIV infection is a type of scarring damage to lymph tissues described as fibrosis. Some early studies of lymph nodes from HIV-infected individuals reported evi...

HIV Replication and Persistence in T Follicular Helper Cells

Following up on the recent post on T follicular helper cells (TFH), a study published on December 17th in the Journal of Experimental Medicine reports that TFH represent a major site of HIV replication and persistence. The finding is not necessariy s...

Dodging HIV Variability by Targeting HERVs

In prior posts I've written about research from the laboratories of Mario Ostrowski and Doug Nixon looking at the effect of HIV infection on human endogenous retrovirus (HERV) protein expression. This work, led by Brad Jones and Keith Garrison, has s...

Immune Activation, Inflammation and HIV Acquisition Risk

The geographic variation in the risk of HIV acquisition among heterosexuals has prompted extensive speculation and debate as to the underlying causes. The lack of a clear explanation has even fueled conspiracy theories, playing a prominent role in Th...

Hepatitis C

HIV i-Base/Treatment Action Group 2012 Pipeline Report Reveals Deep Gaps Between Scientific Promise and Program Delivery

Washington, D.C. -- On the eve of the XIX International AIDS Conference in Washington, D.C., a new report by HIV i-Base (U.K.) and Treatment Action Group (TAG) (U.S.) reveals the deepening gulf between new scientific advances that make it possible to...

Behavior and Circumcision Status Do Not Explain Increased Risk of HIV Acquisition Associated With Ad5-Based Vaccine

In September 2007, the HIV vaccine field received an unexpected setback when it was announced that the phase IIb efficacy trial of a candidate developed by Merck was being stopped early due to lack of efficacy. The trial was conducted by the HIV Vacc...

HIV-Killing Stem Cell Paper Glosses Over Key Caveat

A recent paper describing the engineering of stem cells to generate HIV-specific CD8 T cells has drawn considerable media attention and, regrettably but not untypically, many of the stories are profoundly misleading. Examples of headlines include: "...

Study of HIV Superinfection and Neutralizing Antibody Responses Causes Confusion Img

Study of HIV Superinfection and Neutralizing Antibody Responses Causes Confusion

A recent media report suggested that women infected with two types of HIV may have a better chance of suppressing the virus than women infected with one type of HIV. As Treatment Action Group explains, this report is completely untrue. (On TheBodyPRO...